Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06667141 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
A Phase 1 study of Specific Advanced Solid Tumors, sponsored by Acrivon Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 15
- Study locations
NCT06667141: Recruiting Phase 1 study of Specific Advanced Solid Tumors, sponsored by Acrivon Therapeutics.
NCT06667141 is a Phase 1 study of Specific Advanced Solid Tumors that is actively recruiting participants, run by Acrivon Therapeutics. The registered enrollment target is 100 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% higher). The trial reports 15 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06667141, a Phase 1 study of Specific Advanced Solid Tumors, is actively recruiting participants, sponsored by Acrivon Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.
Primary Outcome
To determine the MTD of ACR-2316.
Conditions Studied
Interventions
- DRUG ACR-2316
Study Locations (15)
California
- Precision NextGen Oncology & Research Center - Beverly Hills
- Hoag Memorial Hospital Presbyterian - Newport Beach
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- Montefiore Medical Centre - The Bronx
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Arizona
- HonorHealth Research Institute - Phoenix
Colorado
- Denver Health One - Denver
Florida
- Florida Cancer Specialist - Sarasota
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-10-08 |
| Est. Completion | 2026-12-12 |
| Phase | Phase 1 |
What NCT06667141 shows while recruiting
NCT06667141 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% higher).
The record links to 1 condition, with Specific Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which ACR-2316 is the first listed.
NCT06667141 lists 15 locations in 12 states (California, New York, Texas).
Frequently Asked Questions
What is clinical trial NCT06667141 about?
NCT06667141 is a clinical study titled "Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors". This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.
What is the current status of trial NCT06667141?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2024-10-08. Estimated completion is 2026-12-12.
What conditions does trial NCT06667141 study?
This clinical trial studies the following conditions: Specific Advanced Solid Tumors.
What interventions are being tested in trial NCT06667141?
The interventions under investigation include: ACR-2316 (DRUG).
Who is sponsoring clinical trial NCT06667141?
This trial is sponsored by Acrivon Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06667141 being conducted?
This trial has 15 study locations across Arizona, California, Colorado, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06667141's enrollment target sits among peer trials
100 547th of 2000 higher than 1,411 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI